Professor Mike Sharland is a globally recognized leader in antimicrobial prescribing, resistance, and healthcare-associated infections in children. He is Professor of Paediatric Infectious Diseases at St George’s, University of London, where he leads the Antibiotic Policy Research Group, a WHO Collaborating Centre for Antimicrobial Policy and Stewardship.

Prof Sharland has served as a senior advisor to the World Health Organization (WHO) for many years, including as a member of the Expert Committee on the Selection and Use of Essential Medicines. He chaired the Antibiotic Working Group of the WHO Essential Medicines List (EML/EMLc), which developed the Access/Watch/Reserve (AWaRe) classification system for antibiotics and the WHO AWaRe Book. He also leads the Wellcome Trust-funded ADILA project, which is developing novel risk-adjusted models for optimal AWaRe antibiotic use globally.

From 2011 to 2018, Prof Sharland chaired the UK Department of Health’s National Expert Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection (APRHAI). He is currently the lead clinical advisor for the neonatal and paediatric programme of the Global Antibiotic Research and Development Partnership (GARDP) and serves as Vice-Chair and AMR lead for the Penta Foundation, a global paediatric infectious diseases research network.

Prof Sharland has pioneered strategies to strengthen the evidence base for paediatric antimicrobial prescribing through cohort studies and clinical trials. He leads multiple international projects funded by EDCTP, EU Horizon 2020, GARDP, NIHR, MRC, and Wellcome Trust, aimed at improving antimicrobial stewardship and combating antimicrobial resistance worldwide.

Tatiana (Taty) is the Operations Manager responsible for the strategic planning and overall direction of the group. She is a group leader with more than 10 years’ experience coordinating and managing a large international portfolio of research studies, including observational studies and phase I-IV adult, maternal, paediatric and neonatal clinical trials funded by national and international agencies and commercial companies. She is a microbiologist by training and joined the PIDRG in 2010 after finishing her PhD in Molecular Biology at Imperial College London.

Aislinn is a senior research fellow in infectious disease epidemiology and has been part of the team since 2017. Her work focuses on using data to inform the optimal use of antibiotics across a range of settings. She has been leading work using data to inform optimal levels of national antibiotic use and the design of a survey methodology for measuring infections and antibiotic use in diverse primary care settings around the world. She also works on clinical trials in the prevention and treatment of neonatal sepsis across Europe, Africa and Asia and trials improving the use of antibiotics in primary care.

Alongside her work at SGUL, Aislinn is pursuing a PhD at University of Oxford modelling antibiotic use data the aim of developing a set of tools that can inform national antibiotic prescribing targets based on clinical infection burden.

Aislinn received her MSc in Control of Infectious Diseases from the London School of Hygiene & Tropical Medicine and her BSc in Biology and Public Health from Tufts University in Boston, USA.

Primarily supporting the Neonatal and Paediatric AMR Team managing and co-ordinating research projects, working closely with global partners & collaborators.

Michael is a technical consultant and project manager working on the ADILA project. His role within this project is to create a geospatially-aware PostgreSQL database to store AMR and AMU data and to then create and manage data pipelines to process, curate, and disseminate these data.

He graduated in Applied Biology at the University of Bath in 1989 and had a subsequent career in information technology within the higher education sector. He worked first at Oxford Brookes University and then at the University of Oxford, building databases and applications to support administrative processes. These included bespoke student record and human resources systems. Over time, he moved into more senior roles, with his ultimate position at IT services at the University of Oxford being Head of Systems Support and Maintenance.

In 2015, Michael joined the Malaria Atlas Project (MAP – www.malariaatlas.org/), which was at the time based in the University of Oxford. He ran a multi-disciplinary team of database designers, computer programmers, map-makers, and research assistants gathering, preparing, and curating the data required for MAP’s geospatial modelling projects.

When MAP relocated to Perth, Western Australia in 2019, Michael joined the GRAM project at the University of Oxford’s Big Data Institute, working with Dr. Catrin Moore to create a geospatially-aware PostgreSQL database to store AMR data.

In January 2021, Michael joined the UK Biobank (University of Oxford) working for Professor Naomi Allen. Michael was responsible for the strategic direction of participant tabular data management as well has running UK Biobank’s two teams of data analysts.

Michael joined the ADILA project at the end of September 2022.

Within Canada, graduated with a Bachelor of Respiratory Therapy (BRT), and worked clinically as a Registered Respiratory Therapist (RRT) in specific fields such as paediatric critical intensive care and anaesthesiology.

Graduated with a Masters (MSc.) in Translational Medicine at St George’s, University of London.

Research focused on antimicrobial health economics and neonatal severe infection.

Currently working as the data manager for the NeoDeco study which is a large cluster randomised control trial aimed at reducing neonatal severe/infection sepsis and resistance bacterial colonisation for high-risk infants (<32 weeks) through optimised kangaroo care and implementation support strategies.

Baboucarr Njie is the Data Manager for the Antimicrobial Resistance (AMR) and Vaccine Team, where he oversees various research projects and leads the development and implementation of data management strategies. He is responsible for the design, maintenance, and optimisation of clinical research databases, ensuring data accuracy, completeness, and integrity across all studies.

With over a decade of experience in clinical data management and research informatics, he has developed specialised expertise in REDCap database design, data cleaning, and process automation. He employs tools such as Power BI and SQL to enhance data analysis, visualisation, and reporting capabilities within the team.

Before joining the AMR and Vaccine Team, he worked as a Data Manager at the MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine (MRCG@LSHTM), where he contributed to several large-scale clinical and epidemiological studies.

He holds a Higher National Diploma (HND) in Computing and Systems Development from Arden University and has completed multiple professional certifications in data management, SQL, and research methodologies. His research contributions include co-authoring a publication in The Lancet Regional Health – Africa on SARS-CoV-2 seroprevalence among pregnant women in The Gambia.

Annie Heath is a Research Associate in the Centre for Neonatal and Paediatric Infectious Diseases at City St George’s, University of London. She holds a Master’s in Epidemiology and Population Health from the London School of Hygiene and Tropical Medicine and a Bachelor’s in Medical Anthropology from the University of Virginia. Her work explores the use of data to improve antibiotic prescribing and inform stewardship interventions predominately with partners in Africa and Asia. Her research interests include maternal and neonatal health, antibiotic use, and infectious diseases.

Gauri is a research project manager currently working on the Fleming Fund-Technical Assistance for Clinical Engagement (TACE) Asia and Africa projects, and NIHR funded NeoSepADAPT. She is also providing support on Wellcome funded AWaRe1 and ADILA projects.

She has a PhD in Medical Microbiology from Kasturba Medical College, Manipal, India.

Hossam is a Research Associate in the Antibiotic Policy Group at the Centre for Neonatal and Paediatric Infection (CNPI). His work focuses on data-driven strategies to optimise antibiotic use and strengthen antimicrobial stewardship. As part of the Fleming Fund TACE grants and ADILA project, he is developing analytical tools to maximise the utility of point prevalence survey (PPS) data to improve prescribing quality in hospitals and primary care, informing policy interventions at local, national, and global levels.

Generally, his research covers infectious diseases, antibiotic prescribing patterns, antimicrobial resistance epidemiology, surveillance evaluation, and health policy in both healthcare and community settings.
Previously, he was a Research Assistant at the NIHR HPRU in Healthcare-Associated Infections and Antimicrobial Resistance at Imperial College London, where he led a meta-analysis on the prevalence, distribution, and risk factors of carbapenem-resistant Enterobacteriaceae across different contexts and worked on linking large healthcare datasets to validate diagnostic guidelines for bloodstream infections in the UK.

Hossam holds a master’s degree in Epidemiology of Infectious Diseases and Antimicrobial Resistance from the University of Glasgow. His research explored antibiotic use and treatment practices from a One Health perspective across human and livestock populations in northern Tanzania.

He has received several prestigious awards, including the UKHSA-funded PhD Studentship at UCL (2025–26), the Chevening Scholarship (2022-23), the Bseisu Foundation Award (2022), and Pfizer’s Global Grant for research training (2022). In his undergraduate studies, he earned an Excellence and Scholastic Achievement Award for ranking among the top of his class (2020).

Juliet Sanyu Namugambe is a Clinical Pharmacist and Research Fellow with the Fleming Fund Technical Assistance for Clinical Engagement (TACE) grants in Africa and Asia. In this role, she supports countries in translating antimicrobial surveillance data into clinically meaningful actions, contributing to the global fight against antimicrobial resistance (AMR). Her work leverages both proven and innovative approaches, including AWaRe-based guidance and the use of quality indicators. Juliet brings over 12 years of experience in health systems strengthening across low- and middle-income countries (LMICs), with expertise in policy development, advocacy, and program implementation at both national and regional levels. She is particularly passionate about medicine quality, AMR, academia, research, and promoting evidence-based practice.

She holds a PhD in Tropical and Infectious Diseases from the London School of Hygiene & Tropical Medicine, a master’s degree in clinical pharmacy (International Practice and Policy) from University College London, and a Bachelor’s degree in Pharmacy from Makerere University in Uganda.

Kyaw Zay Ya is a Research Fellow at the Global Antibiotic Policy Initiative (GAPi), based within the Centre for Neonatal and Paediatric Infection and the Antibiotic Policy Group at the School of Health and Medical Sciences. He is actively involved in research on antibiotic use and resistance, with primary responsibilities that include data analysis for a large-scale GAPi project aimed at identifying optimal antibiotic exposure targets. A medical doctor and health systems researcher, Kyaw brings over a decade of experience in multidrug-resistant tuberculosis (MDR-TB), artemisinin-resistant malaria, and antimicrobial resistance (AMR). His expertise spans health systems research, health economics, and public health programme management, particularly in low- and middle-income countries (LMICs), with professional experience across Myanmar, Sweden, Switzerland, and Singapore.

He holds a PhD (Dr. sc. med.) in Epidemiology and Public Health from the Swiss Tropical and Public Health Institute and the University of Basel, Switzerland, and a Master’s degree in Public Health Sciences, specialising in Health Economics, Policy, and Management, from the Karolinska Institute in Stockholm, Sweden. He completed his medical degree (Bachelor of Medicine and Surgery) at the University of Medicine I, Yangon, Myanmar.

Elise is a Senior Research Project Manager/Clinical Trial Manager supporting multi-country studies through the Global Antibiotic Policy Initiative (GAPi) and the Pregnancy and Infant Preparedness Platform in Europe (PIPELINE).

She earned her Master’s degree in Public Health from the London School of Hygiene and Tropical Medicine.

Liz Tayler is a public health physician who has worked at a high level in UK and international health for thirty years. For the last eight years, she has been coordinating action on Antimicrobial Resistance (AMR) in WHO HQ and the Eastern Mediterranean Region. . She has also been a senior advisor in human development for DFID in Tanzania, Nigeria, and Africa Region and a Director of Quality and deputy director of public health in UK Primary care trusts.

She has practical experience in partnership working, and stimulating collaboration across sectors. She has expertise in designing and managing creative and innovative programmes and funding instruments to improve delivery.

– AMR WHO. Regional Advisor AMR and IPC EMRO, Senior Technical Specialist Egypt. Joint External Evaluation Pakistan. AMR Review missions Iraq Tunisia. Team lead Tripartite Joint Secretariat (WHO FAO WOAH) -.Responsible for the development of the AMR Multi PartnerTrust Fund , Quadripartite Strategic Framework for AMR and poisition papers on AMR and UNSDCF. Team lead National Action Plans and monitoring. Supported National Action Plan development in over 30 countries, Led the development of AMR M and E Framework and TRACSS (Tripartite AMR country self-assessment) system. Lead the development of the AMR community of practice.
– UKDHSC – Design of Fleming Fund
– DFID Tanzania – Development and management of programmes in reproductive health, nutrition, malaria, social protection, WASH , primary education, and innovation in human development
– DFID Africa – Development of PMDUP (Safe abortion) and Evidence for Action (Maternal Health).

Peter Stephens, PhD, has worked for IMS Health for 17 years, and is affiliated with the World Health Organization Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy Analysis, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands. He has previously worked for a pharmaceutical advertising agency and as a representative and brand manager at Beecham Research. He received a Doctor of Philosophy (PhD) degree in Pharmaceutical Policy at Utrecht University in the Netherlands in 2015, a Master’s Degree with Distinction in Marketing in 1995 and a Bachelor of Arts in Archaeology in 1985.

Peter leads IMS’ collaboration with Medicines for Malaria Venture to build the national regulatory authorities’ capacity in Zambia and Uganda to collect, interpret and use pharmaceutical data to aid policy development and pharmacovigilance. Peter works with colleagues at IMS with UNITAID to help build a market intelligence system that will provide comprehensive access to timely, high quality information in the product areas in which UNITAID works. He has worked extensively on IMS’ systems to protect doctor patient confidentiality and became a Core Member of the UK Anonymisation Network.

Peter works with academic institutions, government bodies and multilateral agencies to help understand the impact of pharmaceutical policies on access to medicines, with a recent research focus on the impact of gender, age and deprivation on access to medicines in both developed and lower income countries. Projects have included helping the World Health Organisation track the impact of the economic crisis on the consumption of medicines, and work for a joint Department of Health, NHS and Industry group to understand the extent and reasons for variation in uptake of medicines recommended by the National Institute of Health and Clinical Excellence.

Professor Brian Godman is a prominent figure globally in the field of pharmacoepidemiology and health sciences research. He has a PhD in Pharmacoepidemiology and Health Sciences from the Open University and has been a Visiting Professor at several institutions in recent years including the University of Strathclyde and Sefako Makgatho Health Sciences University in South Africa. His current research focuses on enhancing the rational use of medicines and prescribing efficiency, with a special focus on the management of infectious diseases across multiple low- and middle-income countries to reduce inappropriate antimicrobial use. The activities in Africa build on being part of a small group in 2015 to progress Pan-African medicine utilisation research. He has also contributed to the development of new models to optimize the managed entry of new medicines across countries. Brian has published over 550 papers in peer-reviewed Journals since 2008, with his papers extensively viewed, downloaded and cited since then (https://loop.frontiersin.org/people/14310/overview and https://scholar.google.co.uk/citations?user=UWVb9ysAAAAJ). He is looking forward to being part of the Antibiotic Policy Group at City St Georges.